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Abstract
Background
Laryngotracheal stenosis (LTS) can be either congenital or acquired. Laryngeal stenosis is
most often encountered after prolonged intubation. The mechanism for stenosis following
intubation is believed to be hypertrophic scarring. Mesenchymal stem cells (MSCs) therapy
has shown promising results in regenerative medicine. We aimed to systematically review
the literature on MSC therapy for stenosis of the conductive airways.
Methods
PubMed, EMBASE, Google Scholar and the Cochrane Library were systematically
searched from January 1980–January 2017 with the purpose of identifying all studies
addressing the effect of MSC therapy on the airway. We assessed effect on inflammation,
fibrosis, and MSC as a component in tissue engineering for treating defects in the airway.
Results
We identified eleven studies (n = 256 animals) from eight countries evaluating the effect of
MSCs as a regenerative therapy in the upper airways. The studies indicate that MSC ther-
apy may lead to a more constructive inflammatory response as well as support tissue
regeneration.
Conclusion
There may be a favorable effect of MSCs in inhibiting inflammation and as a component in
tissue engineering. Given the heterogeneous nature of the included animal studies, any
clear conclusion regarding the effect of tracheal stenosis in human subjects cannot be
drawn. The included preclinical studies are however encouraging for further research.
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Introduction
Characteristics of laryngotracheal stenosis
Laryngotracheal stenosis (LTS) is a broad term encompassing narrowing of the airway at the
level of the larynx, subglottis, or trachea. Laryngotracheal stenosis (LTS) is a rare but severe
condition. Besides the functional impairments as a result of airway obstruction, stenosis of the
airways leads to considerable morbidity and mortality. [1,2] The main cause of LTS is intuba-
tion. [3] Current options for treating stenosis involve endoscopic dilation, laser surgery, laryn-
gotracheal reconstruction, or life-long tracheostomy, but are often suboptimal as new scar
tissue frequently develops leading to restenosis. [3,4] It has been suggested that LTS develops
because of altered fibroblast responsiveness to anti-fibrotic signals during mucosal repair lead-
ing to excessive production of fibrosis. [5] Furthermore, there seems to be an altered inflam-
matory response leading to hypertrophic scars and a correlation between early inflammatory
reaction to injury of the mucosa and the degree of scarring. [6]
The initial, preferred and less invasive method of treatment is endoscopic dilation, but this
method has only proven success rates in paediatric patients of 64%; not incorporating the need
for repetitive treatments due to re-stenosis and accompanying morbidity. [3,4] Alternatively,
laryngotracheal reconstruction is required for severe stenosis. [3,7] This procedure holds high
success rate but entails severe risks and subsequent morbidity. [6]
Mesenchymal stem cells
Mesenchymal stem cells (MSCs) are adult multipotent stem cells characterized by their adher-
ence to plastic, their surface antigen expression, and their ability to differentiate into various
connective tissue lineages including adipogenic, chondrogenic, myogenic and osteogenic cells.
[8,9]
MSCs have during the last decades received extensive interest due to their potential thera-
peutic use as treatment for multiple diseases. [10] MSCs have shown anti-inflammatory and
immunosuppressive properties, an ability to migrate to the exact site of injury, and a capacity
to secret soluble factors crucial for cell survival and proliferation with minimal side effects.
[10,11] Furthermore, MSCs currently indicate promising results in regenerative medicine.
[10] In addition, MSCs are easily accessible for isolation most commonly from the bone mar-
row (BM-MSC) or adipose tissue (ASC) and have shown great expansion potential supporting
the prospective of MSCs as a therapeutic agent. It has been shown that ASC increase wound
healing with less scarring in skin ulcers [12] and the prospect of using ASC for therapeutic pur-
pose in treating LTS is promising.
This study systematically evaluated the literature on the effects of MSCs on the conductive
airway. We aimed to clarify the potential of MSCs in the conducting airways in regard to
potentially treating stenosis and to evaluate their potential in a future human trial.
Materials and methods
This systematic review was conducted with reference to the Preferred Reporting Items for Sys-
tematic Reviews (PRISMA) statement. [13]
Systematic literature search and eligibility criteria
In January 2017, one author (KKJ) systematically searched the PubMed, EMBASE, Google
Scholar, Cochrane Library, and clinicaltrials.org for articles in the English and Scandinavian
languages. We included studies evaluating the effect of exogenous supplied MSC on the con-
ductive airway in animals regardless of the publication date. Only studies concerning the
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conductive airways (trachea to the bronchioles) were included. Studies concerning the effec-
tor-mechanisms by which MSCs exert their properties were excluded as were studies evaluat-
ing the effect of MSCs on the airway in combination with other therapeutic regimes. Finally,
studies concerning the effect of MSCs on the alveolar function, lung parenchyma and vascular
bed were excluded. Due to conflict of interests the study done by Macchiarini, P. et al. on clini-
cal transplantation of a tissue-engineered airway was excluded.
The following keywords (MeSH terms included in PubMed) were used: mesenchymal stro-
mal cell, or MSC, or mesenchymal stem cell, adipose derived stromal cells, or adsc preadipo-
cytes, or processed lipoaspirate cells, or stromal vascular fraction cells and Airways when
searching PubMed and Embase. In Google Scholar, clinicaltrials.org and Cochrane Library the
search were performed with the keywords “stem cell” and “airways”.
The following data were extracted from the included studies: study design, study partici-
pants, graft donor, source of graft, intervention, control groups, origin of stem cell, statistical
tests.
Results
The electronic searches identified 251 potentially eligible studies, of which eleven studies (256
animals) met the inclusion criteria (S1 Fig). All studies concerned the use of MSCs as a regen-
erative modality in the treatment of upper airway disease.
It was not possible to perform a meta-analysis due to the great variability in species, source
of the stem cell, evaluation time, disease model, intervention and statistical tests across the
studies.
The effect of MSCs on inflammation in the airway
Five studies (n = 153) evaluated the effect of MSCs on inflammation in the airways, (Table 1).
[14–18] All studies used a preclinical model of induced asthma with either ovalbumin or tolu-
ene diisocyanate (TDI) as an inflammatory sensitizer (Table 1). [14–18]
Three of the studies (n = 100) administered MSCs after sensitization [15,17] while two stud-
ies (n = 53) [14,18] administered the MSCs before the sensitization. [18] All studies used
BM-MSCs and administrated the MSCs via intravenous injection.
All studies could demonstrate a reduction in inflammation in the MSC treated group com-
pared to the control group (Table 1). This was either measured as a significant decrease in the
amount of inflammatory cells peribronchially [14,15,18] a reduction in the total white blood
cell count, or a significant reduction in neutrophiles and eosinophils in blood samples [16,18].
Finally two studies demonstrated a significant reduction in the level of pro-inflammatory cyto-
kines in the circulation in the MSC treated group compared to the control group. [14,17] In
three of the studies the MSCs group was also demonstrated to have a significant reduction in
goblet cell hyperplasia compared to the control group. [15,16,18]
Furthermore, two studies demonstrated a significant reduction in the thickness of the epi-
thelium, the subepithelial smooth muscle layers, and the basement membrane in the upper air-
ways. [15,17]
The effect of MSCs on fibrosis in the airways
Two of the above studies (n = 32) also addressed MSCs effect on fibrosis and collagen deposit
in the upper airway (Table 1). [16,18]
One study on induced asthma was not able to demonstrate a significant change in fibrosis
after administration of MSCs, evaluated by the amount of collagen deposition. [16] Another
study on induced asthma [18] demonstrated an increase in collagen deposition following the
Mesenchymal stem cell therapy for laryngotracheal stenosis
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Table 1. Overview of studies: MSCs and inflammation in the airways.
Author (Year)
[reference]
Animal Origin of
MSCs
Intervention Group(s) Focus of interest Statistic test Study design
Firinci F. et al
(2011) [17]
Mice, 6-
8-week-
old,
weighing
18 to 20 g.
N = 72
Allogenic
from bone
marrow from
mice
Sensitized via
intraperitoneal of chicken
egg albumin with alum as
an adjuvant. After the
sensitization, the mice in
study groups 2 and 3
were exposed to
aerosolized ovalbumin for
30 min per day on three
days a week for eight
weeks, beginning from
the 21st day of the study.
MSCs were administered
following the OVA
nebulization.
1. Control group
2. Ovalbumin induced
asthma only
3. Ovalbumin induced
asthma + MSCs
4. MSCs only
Examination of the
efficacy of MSCs on
lung histopathology
especially remodeling in
a murine model of
chronic asthma
The comparisons
between all groups
were conducted by
using Kruskal–Wallis
method. When
differences were
statistically signicant,
Mann–Whitney U test
was used for group
comparisons.
Controlled trial.
Investigators were
blinded to the
treatment groups
when interpreting
the analyzes.
Mohammadian
M. et al. (2016)
[16]
Mice, 6–8
weeks old.
N = 14
Allogenic
MSC derived
from bone
marrow from
mice
Sensitization by
intraperitoneal injection of
ovalbumin and aluminium
hydroxid and one week
after exposed to
aerosolized OVA for 30
min per day on three days
a week for eight weeks.
MSC were administered
on the last week of OVA
challenge.
1. Control group, not
sensitized
2. Asthma group
3. Asthma+MSC group
Effect of MSCs on lung
pathology and
inflammation in
ovalbumin-induced
asthmatic mice.
Comparison between
groups (control,
asthma and asthma
+MMSC) were
preformed using
analyze with analysis
of variance (ANOVA)
followed by the Turkey
test.
Randomized,
controlled trial.
Ogulur I et al.
(2014) [15]
Mice, 6–8
weeks old.
N = 14
Allogenic
MSC derived
from bone
marrow from
mice
Intraperitoneally
sensitized with chicken
egg albumin and exposed
to aerolized OVA. MSCs
were administered
intravenously just after
the last nebulization of
OVA.
1. Control group
exposed to normal
saline i.p. and then
exposed to
aerolized PBS
2. OVA
3. OVA + MSC
4. PBS + MSC groups
Evaluation of the effect
of MSCs on airway
remodeling and
inflammation in a
ovalbumin-induced
mouse model of chronic
asthma
The difference
between groups was
analyzed with one-way
ANOVA test.
Controlled trial.
Blinded
investigators.
Sun YQ. et al.
(2012) [14]
BALB/c
mice, 4–6
weeks of
age. N = 35
Xenogenic
MSCs from
human bone
marrow
Sensitized by
intraperitoneal injection of
ovalbumin in phosphate-
buffered saline (PBS) on
days 1, 3, 5, 7, 9, 11, and
13. From days 21 to 27
challenged daily with
aerosolized OVA.
Subsequently, mice were
intranasally infused with
OVA. MSCs were injected
via the tail vein at day 0
before the sensitization
and on day 20 after the
sensitization but before
the challenge.
1. Sensitization/
challenge/injection
with PBS/PBS/PBS
2. Sensitization/
challenge/injection
with Naïve/Naïve/
iPSC-MSCs
3. Sensitization/
challenge/injection
with OVA/OVA/PBS
4. Sensitization/
challenge/injection
with OVA/OVA/
iMR90-iPSC-MSCs
5. Sensitization/
challenge/injection
with OVA/OVA/
N1-iPSCS-MSCs
6. Sensitization/
challenge/injection
with OVA/OVA/
BM-MSCs
7. Sensitization/
challenge/injection
with iPSC-MSCs
/OVA/OVA
Evaluation of the effect
of systemic
administration of
BM-MSCs and
iPSC-MSCs on allergic
inflammation in
ovalbumin-induced
allergic inflammation in
upper and lower
airways.
One-way analysis of
variance followed by a
Student-Newman-
Keuls test for multiple
comparisons of the
data with Gaussian
distribution. A Kruskal–
Wallis rank sum test
followed by a Mann–
Whitney U test was
performed for two-
group comparisons of
the data with abnormal
distribution.
Controlled trial. Mice
were subjected to a
single-blind
observation by
examiners who had
no knowledge of the
experimental
groups.
(Continued)
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sensitizer. However, administering MSCs caused that the amount of collagen deposition, only
reached the level in the sham group.
The use of MSCs in tissue repair
Six studies (n = 103) investigated the use of MSCs as a means to induce tissue repair, (Table 2).
[7,19–23]
One study (n = 30) [20], investigated the participation of MSCs in the recovery of injured
airway epithelium. Naphthalene was used to induce lung damage one month after MSC trans-
plantation into the jugular vein. It was observed that BM-MSCs could adhere to the airways
and form patches of epithelial lining in the conductive airways. [20]
Two studies (n = unknown) evaluated the repopulation of decellularized lung scaffold with
MSCs for subsequent clinical transplantation. [21,22] Mendez JJ. et al. [21] showed attachment
to the airways when using MSCs derived from adipose tissue. In regard to epithelization, Men-
dez JJ. et al. showed that MSCs from both bone marrow and adipose tissue underwent epithe-
lial cell differentiation.
This contrasts to Daly AM. et al. [22] that repopulated their scaffolds with BM-MSCs but
their cells did not differentiate into pseudostratified epithelia.
Three studies (n = 73) evaluated the repair of a tracheal defect by surgically replacing the
damaged area with a tracheal graft or a scaffold. [7,19,23] Ott LM. et al. [7] and Gray FL. et al.
[19] used patch-type decellularized scaffold to repair a tracheal defect and investigated if seed-
ing of MSCs onto the scaffold would be beneficial for the tracheal repair, measured by survival
rate, severity of the stenosis, the epithelialization, and histology of the scaffold. Go, T. et al.
(n = 30) [23] investigated the engineering of a functional long-segment graft and replaced six
cm of the trachea with a tracheal graft. The tracheal defects were made on the lamb fetus, and
after the defect was repaired the fetus was returned to the uterine cavity.
Ott LM. et al. found that the survival rate was higher in the BM-MSC group compared to
the scaffold-only group and had a higher level of immature cartilage which could indicate that
BM-MSCs contribute to cartilage formation.
In regards to cross section area and preventing stenosis no clear results exist. Ott LM. et al.
observed a larger cross section area in the scaffold-only group compared with the scaffold
seeded with BM-MSC. Gray FL. et al. did not show a significant difference in cross section
area between the two groups. Gray FL. et al. argued that the scaffolds were made from tracheal
segments of rabbits and were thus not originally programmed to grow or dilate. Go T. et al.
showed that MSC-derived chondrocytes seeded on the external surface resulted in less stenosis
of the tracheal graft. Go T. et al. [23] continued showing the beneficial effect of epithelialization
which help prevent bacterial/fungal contamination.
Table 1. (Continued)
Author (Year)
[reference]
Animal Origin of
MSCs
Intervention Group(s) Focus of interest Statistic test Study design
Lee SH. et al.
(2011) [18]
BALB/c
mice, 6
weeks old.
N = 18
Xenogenic
MSCs from
bone marrow
of rats
Sensitized intranasally by
Toluene Diisocyanate
(TDI). Afterwards animals
were challenged with TDI
through ultrasonic
nebulization. MSCs were
injected intravenously one
day before TDI challenge.
1. Sham
2. TDI
3. TDI + MSCs
Investigated of the
effects of BMDMSCs in
airway remodeling and
inflammation in an
experimental toluene
diisocyanate(TDI)-
induced asthma model.
Continuous data were
compared using the
Kruskal–Wallis test. If
differ- ences were
found to be significant,
the Mann–Whitney U-
test was applied to
compare differences
between two samples.
Controlled trial.
https://doi.org/10.1371/journal.pone.0185283.t001
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Table 2. Study results of the effect of MSCs on tissue engineering.
Author
(Year)
[reference]
Animal Origin of MSCs Intervention Group(s) Focus of interest Statistic test Study design
Ott LM. et al.
(2015) [7]
Rabbits, 7–8 ib.
N = 30
Allogeneic
MSCs from
rabbit bone
marrow
Elliptical defect was made
in the trachea ~ 2 cm
below the cricoid
cartilage. The defect was
patched with a
biomaterial scaffold
patch. The scaffold was
either encapsulated with
TGF-β3, seeded with
BMSCs, or was scaffold-
only.
1. Scaffold-only
2. Scaffold + TGF- β3
3. Scaffold + MSC
Evaluation of a scaffold
for patch-type tracheal
defects and evaluation
of the benefits of adding
cells or growth factor.
Statistical analysis was
preformed using one-
way ANOVA and
Tukey’s post hoc
analysis.
Controlled trial.
The histological
sections were
scored blind by a
pathologist
Gray FL.
et al. (2012)
[19]
Fetal lambs with
tracheal defect.
N = 13
Autologous
MSCs derived
from amniotic
fluid
Complete tracheal
segments from adult
rabbits were
decellularized. Each
decellularized airway
scaffold was then seeded
with labeled aMSCs from
only 1 donor fetus. Fetal
lambs (N = 13) underwent
an anterior longitudinal
cervicotomy followed by a
complete segmental
resection of the native
trachea, with its cranial
border at least 4 tracheal
rings below the cricoid.
1. Tracheal defect
was repaired with
a decellularized
leporine tracheal
segment
2. Tracheal defect
was repaired with
an identical graft
seeded with
expanded/labeled
autologous aMSCs
Examination of
possibilities for tracheal
repair with either a
decellularized airway
scaffold or a graft
engineered from
autologous amniotic
mesenchymal stem cells
(aMSCs).
Statistical comparisons
were by 2-way
repeated- measures
analysis of variance
and the Fisher’s Exact
test, as appropriate
Controlled trial.
Mendez JJ.
et al. (2014)
[21]
Rats, 3–5
months old.
N = unknown
Xenogenic
MSCs from
human bone
marrow and
human adipose
tissue
Rat lungs were
decellularized, followed
by seeding the matrix with
hBM-MSCs or hAT-MSC
1. Decellularized rat
lungs seeded with
MSCs from bone
marrow
2. Decellularized rat
lungs seeded with
MSCs from
adipose tissue
Ability of hBM-MSCs
and hAT-MSCs to
repopulate acellular
rodent lung tissue.
T-tests were performed
to evaluate whether two
groups were
significantly different
from each other
Cohorte study
Daly AM.
et al. (2012)
[22]
Mice, 8–24
weeks. Adult
rats, 16 weeks.
(N = unknown)
Allogeneic
MSCs from
bone marrow of
adult male mice
Lungs were
decellularized and
afterwards reseeded with
MSCs.
1. Decellularized rat
lungs seeded with
MSCs from bone
marrow
Examination of the
structural features of the
decellularized lung and
examination of the
growth and
differentiation of MSCs
on decellularized lung
tissue.
Differences between
results were assessed
by unpaired t-test.
Statistical analyzed by
one-way analysis of
variance (ANOVA) with
Bonferroni post hoc
analysis and post-test
Dunnett or Newman-
Keuls multiple
comparison analyses
Cohorte study
Serikov VB.
et al. (2007)
[20]
Mice, 3-5-week-
old. N = 30
Allogeneic
MSCs from
bone marrow of
adult male mice
Animals received
sublethal dose of whole-
body irradiation the day
before they were infused
with MSC into the jugular
vein. One month after
MSC transplantation
either naphthalene IP in
corn oil or corn oil without
naphthalene (control)
where administered.
1. MSC
transplantation
+ no naphthalene
2. MSCs
+ naphthalene
3. MSCs
intratracheal
4. No intervention
5. Control
Examination of the
participation of BM-cells
in the process of airway
epithelial restoration
after naphthalene-
induced injury.
Statistical analysis was
performed using Mann–
Whitney–Wilcoxon test
Controlled trial.
(Continued)
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Discussion
To the best of our knowledge, this study is the first systematic review to evaluate the effect of
mesenchymal stem cells in the conducting airway and its therapeutic preclinical potential for
treating laryngotracheal stenosis. As we identified no studies specifically evaluating the effect
of MSCs in regards to treating stenosis by injecting stem cells into the airways, this review
highlights the effects of MSCs on the airways in a general setting. The goal of the study was
to investigate the effects of MSCs on the airway as a preclinical study to evaluate if it could be
possible to treat stenosis by injection of stem cells to the airway. The result of our study
highlighted three main areas respectively the impact on inflammation, on fibrosis and in tissue
repair.
The studies included in this review differed in regards to origin of MSCs, the dose of MSCs,
the study design, the animal model and the disease model. Collectively, both mice, rats, rabbits,
pigs and lambs were used as experimental models. MSCs were derived from bone marrow, adi-
pose tissue and amnion fluid and were extracted from different species including both human,
mice, rats, rabbits, pigs, and lambs. Especially, the studies investigating MSCs in regards to tis-
sue engineering differed considerably in methods and design and it is thus difficult to integrate
the results. Furthermore, only two of the eleven studies included in this review reported ran-
domization and only four studies reported blinding when analyses were performed. This is
important to bear in mind in regards to potential biases. The studies also differed considerable
in regards to the time MSCs were administered as compared to the intervention the animals
were exposed to.
As stenosis of the airways is a process characterized by fibrotic wound healing [5] and
altered inflammation [6] it is relevant to see if alteration of these factors using MSCs would
adjust the development of stenosis. Inhibiting the healing process by inhibiting inflammation
and fibrosis would possibly prevent scar tissue formation and prevent a reduced cross-
Table 2. (Continued)
Author
(Year)
[reference]
Animal Origin of MSCs Intervention Group(s) Focus of interest Statistic test Study design
Go, T. et al.
(2010) [23]
Pigs, 65 +/- 4 kg.
N = 30
Autologous
MSCs derived
from bone
marrow
Trachea was retrieved
from 10 donors.
BM-MSCs and mucosal
epithelial cells were
obtained from 20
intended recipients. 6 cm
of the trachea in the
recipients were replaced.
Animals were observed
for a maximum of 60
days. Tracheas were
harvested and evaluated
postmortem.
1. 6 cm of trachea
was replaced with:
decellularized
matrix
2. 6 cm of trachea
was replaced with:
decellularized
matrix and
external,
autologous MSC-
derived
chondrocytes
3. 6 cm of trachea
was replaced with:
decellularized
matrix with
internal,
autologous
epithelial cells
4. 6 cm of trachea
was replaced with:
decellularized
matrix with both
types
Examination of the
relative contribution of
epithelial cells and MSC-
derived chondrocytes to
the survival of tissue-
engineered airway
transplants in pigs.
Continuous variables
were compared by
using the independent-
samples t test
Randomized,
controlled trial.
https://doi.org/10.1371/journal.pone.0185283.t002
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sectional area of the airway. However, the consequence of impaired healing has not yet been
investigated.
Another modality of treating severe stenosis with a significant narrowing of the airways, or
a long-segment airway stenosis is by creating a graft to substitute the narrow area of the airway.
A graft could be helpful in treating both acquired and congenital stenosis. The majority of the
studies agreed upon the effect of MSCs in increasing epithelialization. Go, T. et al. showed the
importance of epithelialization to avoid infections and to create a functional graft. When deal-
ing with laryngotracheal stenosis it is essential to increase the cross-section area and to con-
struction of a functional graft that can expand and widen the airway. The results on the effect
of MSCs to aid in increasing the cross-section area were not conclusive.
Mendez JJ. et al. [21] concluded that MSCs derived from adipose tissue would be more ben-
eficial than MSCs derived from BM when constructing a patch-type scaffold. Still a lot remains
to be investigated such as the possible improved effects of MSCs derived from adipose tissue
and if MSCs from adipose tissue is more beneficial in treating subglottic stenosis.
So far no studies on the effect of stem cells and their effect in the airways have been con-
ducted in human trials. Animal studies are associated with a great deal of methodological
problems that must be taken into account before the study can be transferred to humans.
Methodological problems of animal experiments include difference and variation of metabolic
pathways between disparate animal species. Furthermore, variations in dosing regime between
human and animals exists as well as variability in methods of randomization, nuances in labo-
ratory technique, and variability in the choice of comparison. [24,25]
This systemic review of the existing animal experiments do represent an important step
towards a human trial. [24,25]
In conclusion there are various effects of MSCs on the airways with consistent responses
towards inflammation, whereas the effects on fibrosis and tissue repair were contradictory pos-
sibly related to methodological differences. Thus it is difficult to summarize the findings into a
coherent conclusion. The presented results suggest that MSCs have potential in treating laryn-
gotracheal stenosis but many issues remain to be investigated. Altogether, however, we find
that the above-mentioned findings are encouraging for conducting a clinical study.
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